Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies.
Immunowake has raised $20.0M in total funding. The most recent round was Series A. The last funding was announced in May 2022.
Immunowake's investors include Lapam Capital, South China Venture Capital, HEDA Ventures, Hyfinity Investments.
Immunowake is headquartered in Birmingham, United States.
Immunowake is a biotechnology company that focuses on identifying new therapies for patients who do not respond to existing immunotherapies.
Immunowake is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immunowake — Funding & Investors." VCBacked, May 15, 2022, https://www.vcbacked.co/company/immunowake. Accessed September 30, 2026.
VCBacked. (2022). Immunowake — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/immunowake
{{cite web |title=Immunowake — Funding & Investors |url=https://www.vcbacked.co/company/immunowake |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated